- Lead matrixed cross-functional Translational Science Teams across early-stage (CAN-PhII) oncology antibody-drug conjugate (ADC) programs, including strategies to support clinical development, IND-readiness, resourcing, and regulatory filings (~2-4 IND submissions annually) - Represent Translational Sciences functions at Global Product and Development Teams and relevant program review and executive governance bodies

Biological and Environment Sciences and Engineering (US-based) - Designed and developed business plan, operating and funding model for the first private clinical genomics company in Saudi Arabia (https://www.noordx.sa/) - Successfully raised 2M SAR (500K USD) seed fund, facilitating Series A of c.20M SAR (5.3M USD) - Established 5 pre-launch partnerships (undisclosed) with top-tier genomics institutes and health techs in USA, France, and Australia; drafted, negotiated, executed contracts and term sheetsIndustry Collaborations, Innovation & Economic Development (Saudi-based) - Oversaw industry collaboration and partnership activity (~50+ industry companies) across 11 KAUST Engineering Research Centers; led a team of 3 PhD-level professionals and 11 industry liaisons - Managed the industry partner portfolio in key areas of focus across KSA (healthcare, materials chemistry, energy, water desalination); contributed to strategic life science roadmap Integrative Activities, Office of Competitive Research Funds (Saudi-based) - Developed bold, interdisciplinary research initiatives (~$10M) in multiple science and engineering domains; program yielded >50 faculty publications and additional patent applications pending (2016-2017) - Partnered with US National Academy of Sciences, Office of Naval Research – Global (ONR-G), Saudi Arabia General Investment Authority (SAGIA) - Comprehensive business process mapping analyses across 7 work streams, 46 FTEs, and successfully introduced new methods and workflows; introduced integrated research management platform (MIT COEUS)

Office of BioTherapeutics R&D SVP and Pfizer Cambridge Site Head Executive Group - Managed translational research activities across 4 Research Units and 3 Partner Lines to support BioTx operating model (End-to-End Biologics) and progression of the portfolio across early development (LD/CAN - PoC PhIIb); therapeutics areas: Immunology & Inflammation; Rare Disease; Oncology; Neuroscience - Developed 23andMe 10K IBD and 5K Lupus patient communities; extended Research Accelerator to support patient-centric approach to Precision Medicine - Led the MIT Synthetic Biology Center alliance to support streamlined biologic production capabilities through the technology transfer of proprietary genomic excision and targeted gene integration technology - Explored new ventures with VC/PE firms to support spin-in of technologies to support or complement PFE clinical research, development, and precision medicine priorities - Managed the BioTherapeutics R&D Drug Discovery Meeting to provide project and partner line teams a review forum with scientific and clinical leaders from top academic and medical institutions

- Founded and recruited R&D team; initiated start-up research operations, regulatory filings, and CRO projects; scouted and co-designed incubator facility build-out - Led founding research team in preliminary pharmacology POC technology studies with discovery stage preclinical assets; created and developed an extensive database of over 200 potential preclinical pipeline candidates - Lead inventor on 23 issued and pending patents across a broad range of DNA and RNA technologies and therapeutic applications via coordinated R&D and business strategy - Managed seed financing and individual research project budgets

Venture Capital and Private Equity FirmPerformed in-depth market, technology, and IP analyses to support the launch of life science NewCosCollaborated directly with Flagship Venture Partners and academic leads at Harvard, MIT, and MGH

Developed a chemical method of synthetic DNA replication in a cell-like nanoparticleContributed to the development of the NSF Chemical Bonding Center Phase I

Dissertation Advisor: Jack W. Szostak, 2009 Nobel Laureate in Medicine.Worked with Frederick W. Alt, Charles A. Janeway Professor of Pediatrics at Children's Hospital Boston

Advisor: Kathryn W. Tosney